Characteristics | N (%) 173 (100%) |
---|---|
Gender | |
 Male | 70 (40.5) |
 Female | 103 (59.5) |
Age, years | |
 Median, IQR | 34 (28–44) |
 15–24 | 25 (14.5) |
 25–34 | 68 (39.3) |
 35–44 | 40 (23.1) |
 45–54 | 26 (15.0) |
 55–64 | 9 (5.2) |
 > 64 | 5 (2.9) |
Educational level | |
 None | 51 (29.5) |
 Primary | 19 (11.0) |
 Secondary | 88 (50.9) |
 Tertiary | 15 (8.7) |
Marital Status | |
 Married | 52 (30.1) |
 Single | 116 (67.0) |
 Unknown | 5 (2.9) |
Occupation | |
 Trader/Business | 68 (39.3) |
 Student | 19 (11.0) |
 Unemployed | 4 (2.3) |
 Other | 82 (47.4) |
Risk factors | |
 Smoking | 35 (20.2) |
 Alcohol use | 39 (22.5) |
 Illicit drugs | 9 (5.2) |
HIV status | |
 Known before admission | |
  < 12 months | 21 (12.2) |
  > 12 months | 53 (30.6) |
 Diagnosed during hospitalization | 89 (51.4) |
 Unknown | 10 (5.8) |
ART regimens, N = 64 (100%) | |
 TDF + 3TC + EFV | 54 (84.4) |
 AZT + 3TC + NVP | 7 (10.9) |
 AZT + 3TC + EFV | 1 (1.6) |
 AZT + 3TC + LPV/r | 2 (3.1) |
CD4 count, cells/μL, N = 112 (100%) | |
 Median, IQR | 87 (25–266) |
 < 100 | 56 (32.3) |
 100–199 | 22 (12.7) |
 200–349 | 15 (8.7) |
 ≥ 350 | 19 (11.0) |
 Not obtained | 61 (35.3) |
WHO clinical staging | |
 Stage 1 | 1 (0.6) |
 Stage 2 | 28 (16.1) |
 Stage 3 | 115 (66.5) |
 Stage 4 | 29 (16.8) |